VIRX
Viracta Therapeutics (VIRX)
$03
About Viracta Therapeutics (VIRX)
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.
Details
Daily high
$0.03
Daily low
$0.02
Price at open
$0.03
52 Week High
$1.31
52 Week Low
$0.01
Market cap
1.0M
Dividend yield
0.00%
Volume
122,186
Avg. volume
410,897
P/E ratio
-.02
Viracta Therapeutics News
Details
Daily high
$0.03
Daily low
$0.02
Price at open
$0.03
52 Week High
$1.31
52 Week Low
$0.01
Market cap
1.0M
Dividend yield
0.00%
Volume
122,186
Avg. volume
410,897
P/E ratio
-.02